Dr. Kristen Spencer, MD
Claim this profileRutgers Cancer Institute of New Jersey
Studies Cancer
Studies Tumors
14 reported clinical trials
46 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
KRAS positive
2Tumors
Stage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Kristen Spencer, MD is currently running
Avutometinib + Defactinib + Chemotherapy
for Pancreatic Cancer
This trial tests a new treatment combining two experimental drugs with two existing treatments for patients with newly diagnosed pancreatic cancer. The goal is to see if this combination can safely and effectively stop cancer growth and kill cancer cells. The study focuses on patients who have not yet received any treatment. One of the existing treatments used in the trial has been important in pancreatic cancer treatment but offers only modest improvements in symptoms and survival.
Recruiting1 award Phase 1 & 27 criteria
Peposertib + Avelumab + Radiation
for Hepatobiliary Cancer
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving peposertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies.
Recruiting1 award Phase 1 & 210 criteria
More about Kristen Spencer, MD
Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Kristen Spencer, MD has experience with
- Atezolizumab
- Nab-paclitaxel
- Nivolumab
- Oxaliplatin
- Panitumumab
- Olaparib
Breakdown of trials Kristen Spencer, MD has run
Cancer
Tumors
Adenocarcinoma
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kristen Spencer, MD specialize in?
Kristen Spencer, MD focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kristen Spencer, MD currently recruiting for clinical trials?
Yes, Kristen Spencer, MD is currently recruiting for 4 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Kristen Spencer, MD has studied deeply?
Yes, Kristen Spencer, MD has studied treatments such as Atezolizumab, Nab-paclitaxel, Nivolumab.
What is the best way to schedule an appointment with Kristen Spencer, MD?
Apply for one of the trials that Kristen Spencer, MD is conducting.
What is the office address of Kristen Spencer, MD?
The office of Kristen Spencer, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.